Navigation Links
Ulcerative in Medical Technology
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...
-- Phase 1 RDEA119 data expected in second half of 2008 -- -- Presentation at the Seventh Annual JMP Securities Research Conference on May 21st canceled; webcast of corporate update scheduled during Ardea's Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT -- SAN DIEGO, May...
4.8 g/day dose using investigational 800 mg tablet demonstrated efficacy and was well tolerated in ASCEND III study SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- In a study presented today at the 39th Annual Digestive Disease Week (DDW) meeting in San Diego, California, 70 percent ...
A Separate Retrospective Analysis of US Employer Claims Suggests a Benefit of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with Inflammatory Bowel Disease SAN DIEGO, May 20 /PRNewswire/ -- Data from a new analysis of the Active Ulcerative Colitis Tri...
SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA(TM), will be presented today at Digestive Disease Week (DDW). Study 302 (further referr...
Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week 2008 PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully h...
Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an eff...
Symptom resolution results based on stringent endpoint of clinical remission is more clinically relevant, beneficial to patients PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- An analysis of data to be presented tomorrow at the American College of Gastroenterology (ACG) Annual Scientif...
Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...
Separate Survey Underscores Impact of Disease on Work Status and Productivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findings presented today at Digestive Disease Week(R) 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects wi...
AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to trea...
...for the treatment of moderately to severely active ulcerative colitis, in patients with an inadequate response t...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...enage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE and azathioprine ...
...ting patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior V...inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In prec... prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 cli...
...100 in a range of inflammatory diseases, including ulcerative colitis in an ongoing companion Phase 2 study." ...MDX-1100 is also being explored as a treatment for ulcerative colitis (UC). A Phase 2 randomized, double-blind, ...ucosal inflammation ascertained by endoscopy. ulcerative colitis is a chronic inflammatory bowel disease ch...
...ultaneous Studies to Investigate Novel Therapy for ulcerative Colitis and Crohn's Disease OSAKA, Japan, Jan...ogram, will study vedolizumab for the treatment of ulcerative colitis and Crohn's disease, the two main types of...ove the lives of patients with Crohn's disease and ulcerative colitis." Though current IBD treatments have ...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...
...ed chronic colitic mice. The beneficial effect of RDEA119 exceeded that of Remicade(R) (infliximab), the current standard-of-care for the treatment of ulcerative colitis. "Blocking the MEK1/2 pathway appears to be a promising strategy for treating inflammatory disease, for which a significant unmet medical ne...
...apy that the FDA has approved for the treatment of ulcerative colitis, a related inflammatory bowel disease, and...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...itis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. ...
... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...or equal to one percent with PEGINTRON(TM): Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...-1100 represents a breakthrough mechanism of action for inflammatory disease and is being investigated in separate Phase 2 proof-of-concept trials for ulcerative colitis and rheumatoid arthritis. Interim data from these trials are expected in 2009. -- MDX-1401 is a fully human antibody that targets CD30, a me...
... a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007. "The initiation of this proof-of-concept stud...is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for no...
...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...
... the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's d...
...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
-- Phase 1 RDEA119 data expected in second half of 2008 -- -- Presentation at the Seventh Annual JMP Securities Research Conference on May 21st canceled; webcast of corporate update scheduled during Ardea's Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT -- SAN DIEGO, May...
4.8 g/day dose using investigational 800 mg tablet demonstrated efficacy and was well tolerated in ASCEND III study SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- In a study presented today at the 39th Annual Digestive Disease Week (DDW) meeting in San Diego, California, 70 percent ...
A Separate Retrospective Analysis of US Employer Claims Suggests a Benefit of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with Inflammatory Bowel Disease SAN DIEGO, May 20 /PRNewswire/ -- Data from a new analysis of the Active Ulcerative Colitis Tri...
SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA(TM), will be presented today at Digestive Disease Week (DDW). Study 302 (further referr...
Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week 2008 PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully h...
Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an eff...
Symptom resolution results based on stringent endpoint of clinical remission is more clinically relevant, beneficial to patients PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- An analysis of data to be presented tomorrow at the American College of Gastroenterology (ACG) Annual Scientif...
Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...
Separate Survey Underscores Impact of Disease on Work Status and Productivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findings presented today at Digestive Disease Week(R) 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects wi...
Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
LONDON, 2 July 2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, today announces positive results for its Phase II proof-of-concept study for HMPL-004 in mild-to-moderate Ulcerative Colitis, a form of inflammatory bowel disease. The trial met its objectiv...AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to trea...
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
...release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammatio...as 79 percent in ASCEND III and 74 percent in ASCEND II. (1,2) About ulcerative Colitis (UC) UC involves inflammation of the lining of the colon and re......for the treatment of moderately to severely active ulcerative colitis, in patients with an inadequate response t...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...enage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE and azathioprine ...
Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
...rentiating IBD vs. non-IBD and Crohn's disease vs. ulcerative colitis than using traditional cutoff value analys...tibility. It is estimated that Crohn's disease and ulcerative colitis, the two main types of IBD, together affec...S. The main difference between Crohn's disease and ulcerative colitis is the location and nature of the inflamma......ting patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior V...inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In prec... prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 cli...
...100 in a range of inflammatory diseases, including ulcerative colitis in an ongoing companion Phase 2 study." ...MDX-1100 is also being explored as a treatment for ulcerative colitis (UC). A Phase 2 randomized, double-blind, ...ucosal inflammation ascertained by endoscopy. ulcerative colitis is a chronic inflammatory bowel disease ch...
Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
...y is also looking at Leukotoxin for use in autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, lupus, Crohn's disease and ulcerative colitis. "While there are numerous drug candidates under development for treating various forms of leukemia, Dr. Kachlany's approach to utilizing......ultaneous Studies to Investigate Novel Therapy for ulcerative Colitis and Crohn's Disease OSAKA, Japan, Jan...ogram, will study vedolizumab for the treatment of ulcerative colitis and Crohn's disease, the two main types of...ove the lives of patients with Crohn's disease and ulcerative colitis." Though current IBD treatments have ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
...flammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets; SAPHRI......than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...
...ed chronic colitic mice. The beneficial effect of RDEA119 exceeded that of Remicade(R) (infliximab), the current standard-of-care for the treatment of ulcerative colitis. "Blocking the MEK1/2 pathway appears to be a promising strategy for treating inflammatory disease, for which a significant unmet medical ne...
...apy that the FDA has approved for the treatment of ulcerative colitis, a related inflammatory bowel disease, and...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...itis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. ...
... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...
New Genes Found for Inflammatory Bowel Disease in Children
...ase, which can affect any part of the gastrointestinal tract, and half have ulcerative colitis, which is limited to the large intestine. IBD that begins in chil...omized to each patient." The study team also found an association between ulcerative colitis and genes on the major histocompatiblity complex (MHC) on chromosom......than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...or equal to one percent with PEGINTRON(TM): Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...-1100 represents a breakthrough mechanism of action for inflammatory disease and is being investigated in separate Phase 2 proof-of-concept trials for ulcerative colitis and rheumatoid arthritis. Interim data from these trials are expected in 2009. -- MDX-1401 is a fully human antibody that targets CD30, a me...
... a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007. "The initiation of this proof-of-concept stud...is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for no...
...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...
... the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's d...
...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
...to accumulate in the GI tract, liver and bone in animals, the clinical significance in humans is unknown. -- Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL clinical studies. Caution should be used in patients with these...Other TagsOther Contents
EMSAarrayCGHMitoSciencePDHKineticScanFACSVantageSTREXHCSArrayScanMountableSAPK1bJNK3ViaSureBioconjugation
(Date:5/17/2013)... An international team of scientists using a new ... inside a living frog embryo in greater detail than ... advance biological research and the search for new treatments ... Karlsruher Institut fr Technologie in Germany, in collaboration with ... Energy,s Argonne National Laboratory, released the most precise depiction ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... living closer to a fast food restaurant had a ... further away from fast food, according to researchers at ... this association was particularly strong among those with a ... in the American Journal of Public Health ... fast food restaurant, and among lower-income African-Americans, the density, ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3(Date:5/20/2013)... WA (PRWEB) May 20, 2013 6Webs.com ... home alarm system reviews . 6Webs.com recently completed their ... the nation. Reviews are completed annually and the top ... factors which include their monitoring technology, equipment and warranties ... 6Webs.com stated, "When the 6Webs.com team completed the home ...
(Date:5/20/2013)... News) -- Dermatologists are saying that new federally ... make smarter choices when it comes to products ... new labels required by the U.S. Food and ... a sunscreen will protect against skin cancer in ... indicate whether a sunscreen is water-resistant, according to ...
(Date:5/20/2013)... Irving, Texas (PRWEB) May 20, 2013 ... and Phytel, the leader in automated, provider-led population ... health systems to effect change and successfully pursue ... of advisory services and technology to accelerate the ... of the VHA IMPERATIVTM performance improvement suite of ...
(Date:5/20/2013)... University in Sweden have mapped the significance of ... studies have previously examined whether different forms of ... coronary heart disease, ischemic stroke, peripheral arterial disease ... siblings and parents have suffered different types of ... is highest for atherosclerosis of the aorta followed ...
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
Breaking Medicine News(10 mins):Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3[0] Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com[0] Revised Sunscreen Labels Should Help Consumers Make Wiser Choices[0] VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings[0] Atherosclerotic disease heredity mapped in nationwide study[0] Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |